Novo Nordisk A/S

Novo Nordisk uses recombinant DNA technology to make innovative products for people with diabetes. We first marketed insulin for commercial use in 1923, and today we offer a comprehensive line of human insulin and insulin analog products. Novo Nordisk created the world's first insulin pen device, and now we are a world leader in production and distribution of these revolutionary insulin delivery systems.